Dr. Jürgen Böhm and Josef Bogenschütz complete the line-up of the management board at Medos

Medos AG is preparing for the step up to becoming a complete provider in the area of cardiac surgery by recruiting the former Maquet managers Dr. Jürgen Böhm und Josef Bogenschütz.

On the 1st August, heart surgeon Dr. Jürgen Böhm and graduate engineer Josef Bogenschütz became members of the management board at Medos Medizintechnik AG and, in so doing, completed the line-up. As a result, there will be a clear focus on the continuous development of a predetermined product range for cardiac surgery and cardiovascular technology. Dr. Böhm is responsible for clinical management, marketing, new business developments and certification and Mr. Bogenschütz for sales, research and development, production and quality management. Dr. Volker Hamm, spokesperson of the management board, is, as before, responsible for the areas of finance, human resources, IT and purchasing.

"I am very much looking forward to working with Mr. Bogenschütz and Dr. Böhm", said Dr. Hamm. "Along with their proven leadership qualities, both have considerable expertise in the development and marketing of products and services pertaining to cardiac surgery. As a result, we are ideally placed to develop our status as an innovative and continually stable partner for heart surgeons and cardiovascular engineers.”

"Medos has the potential to develop into a gem of a technology company, with a stable future in cardiac surgery applications as well as other peripheral markets“, according to Dr. Böhm. "I am particularly looking forward to having close personal contact with our customers, in order to address their wishes and to instigate the development of successively improved and novel approaches to creating innovative therapy solutions." Mr. Bogenschütz makes it clear that Medos will invest heavily when it comes to expanding the product range and "will continue to concentrate on top quality products - made in Germany. Our aim is to expand our position as complete provider in the area of cardiac surgery."

Thomas Villinger, managing director of the German company Zukunftsfonds Heilbronn, or zfhn for short, (full owner of Medos since the beginning of 2011) emphasises that the objective is "to establish Medos as a healthy, German, fast-growing, midsize company specialising in medical devices. With the new board members, Mr. Bogenschütz and Dr. Böhm, we are providing Medos with a powerful engine to help achieve this objective."

Dr. Böhm can draw on four years' experience working as clinical director at Maquet Cardiopulmonary AG in Hirrlingen, Germany and likewise at Maquet Cardiovascular in Wayne, USA. The 44-year old doctor was active for many years at Sana Herzchirurgischen Klinik (Sana heart surgery clinic) in Stuttgart. The heart surgeon, who acquired a teaching qualification at Eberhard-Karls-Universität in Tübingen, Germany, switched to the medical devices sector four years ago.
Mr. Bogenschütz was most recently the chairman of the management board at Maquet Cardiopulmonary AG. The 45-year old engineer began his career in the manufacturing sector, working at Bizerba GmbH and Beru AG, before switching to the medical devices sector eleven years ago, when he joined Jostra AG.

Background information

Medos AG
Medos AG is a leading, midsize, high-tech, German company specialising in medical devices, that develops, manufactures and globally markets products used for cardiac surgery as well as peripheral applications. From the very beginning, Medos has focussed on the quality of development and production, adopting a "Made in Germany" approach. Consequently, the complete range of products for cardiac surgery operations is manufactured using high technology at the German production facilities in Stolberg and Radeberg, products which have already been used for thousands of patients.

The product range fundamentally comprises Medos tube sets and also includes in-house developments such as HILITE® oygenators and reservoirs, RHEOPARIN® coatings (heparin), the DELTASTREAM® series, Medos VAD system products with various ventricles and cannulae, and a comprehensive set of Medos cannulae.

Zukunftsfonds Heilbronn
The German equity firm Zukunftsfonds Heilbronn (zfhn), formed in 2006, assists early-stage, technology-based companies in North Würtemberg, from the start-up stage, where innovative ideas are developed, through to successful establishment. It concentrates on sunrise sectors such as life sciences, IT and energy, industrial and environmental technologies. The companies receive long-term support from zfhn and become established in the economic region of Heilbronn. Alongside the high business expertise of its managers and administrators, the main strength of the equity firm is its excellent regional and international business connections.

Judith Reiners
Head of Marketing
Obere Steinfurt 8-10
52222 Stolberg
Germany
j.reiners@medos-ag.com

This release was published on openPR.